AUGMEROSEN
Recurrent Grade 3 Follicular Lymphoma
National Cancer Institute (NCI)nucleic_acidPhase 2Dormant
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Recurrent Grade 3 Follicular Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE David Bond, MD | Phase 3 | BBB |
Ifosfamide David Bond, MD | Phase 2 | BBB |
FILGRASTIM Fred Hutchinson Cancer Center | Phase 3 | BBB |
Carboplatin David Bond, MD | Phase 2 | BBB |
PEGFILGRASTIM Mayo Clinic | Phase 2 | BB |
Ixabepilone National Cancer Institute (NCI) | Phase 2 | B |
Same molecule, other indications
AUGMEROSEN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →